Topical treatments for Seborrheic Keratosis: A systematic review
https://doi.org/10.47895/amp.v54i3.1672
- Author:
Ma. Celina Cephyr C. Gonzalez
1
;
Veronica Marie E. Ramos
1
;
Cynthia P. Ciriaco-Tan
1
Author Information
1. Department of Dermatology, College of Medicine and Philippine General Hospital, University of the Philippines Manila
- Publication Type:Other Types
- Keywords:
Topical
- MeSH:
Keratosis, Seborrheic;
Systematic Review
- From:
Acta Medica Philippina
2020;54(3):305-312
- CountryPhilippines
- Language:English
-
Abstract:
Background:Seborrheic keratosis is a benign skin tumor removed through electrodessication, cryotherapy, or surgery. Alternative options may be beneficial to patients with contraindications to standard treatment, or those who prefer a non-invasive approach.
Objectives:To determine the effectiveness and safety of topical medications on seborrheic keratosis in the clearance of lesions, compared to placebo or standard therapy.
Methods:Studies involving seborrheic keratosis treated with any topical medication, compared to cryotherapy, electrodessication or placebo were obtained from MEDLINE, HERDIN, and Cochrane electronic databases from 1990 to June 2018.
Results:The search strategy yielded sixty articles. Nine publications (two randomized controlled trials, two non-randomized controlled trials, three cohort studies, two case reports) covering twelve medications (hydrogen peroxide, tacalcitol, calcipotriol, maxacalcitol, ammonium lactate, tazarotene, imiquimod, trichloroacetic acid, urea, nitric-zinc oxide, potassium dobesilate, 5-fluorouracil) were identified. The analysis showed that hydrogen peroxide 40% presented the highest level of evidence and was significantly more effective in the clearance of lesions compared to placebo.
Conclusion:Most of the treatments reviewed resulted in good to excellent lesion clearance, with a few well-tolerated minor adverse events. Topical therapy is a viable option; however, the level of evidence is low. Standard invasive therapy remains to be the more acceptable modality.
- Full text:1672-Article Text-7819-1-10-20200623.pdf
